Part2: Sexual desire peptide PT141 surpassing GLP-1
Uniqueness of MC4R agonists Pt141
The currently popular GLP-1 drugs, although able to delay gastric emptying and reduce appetite, cannot solve the underlying logic problem of energy metabolism. Patients often suffer from muscle loss and premature plateau when using drugs such as semaglutide. The uniqueness of MC4R agonists lies in their direct action on POMC neurons in the hypothalamus, the “master switch” for energy balance in the human body. Pt141 surpassing GLP-1 for muscle loss .
Pt141: Weight loss without muscle contraction
When Bremelanotide binds to MC4R, it triggers a cascade reaction: on the one hand, it inhibits AgRP neurons that produce hunger signals, increasing the brain’s sensitivity to leptin by three times; On the other hand, it activates the sympathetic nervous system, promoting the browning of white adipose tissue (i.e. converting it into brown fat that burns calories). Preclinical studies have shown that this dual effect can increase basal metabolic rate by 15-20%, equivalent to automatically consuming 200 calories per day. More importantly, it may break through the bottleneck of existing weight loss drugs that do not shrink fat. Research has shown that MC4R activators can specifically target visceral fat, increasing the rate of abdominal fat breakdown to three times the conventional level.
